Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing ...
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free ...
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, ...
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on IO Biotech ...
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology ...
Thu, August 14, 2025 at 10:07 PM UTC Io Biotech (NASDAQ:IOBT), a clinical-stage oncology company specializing in cancer vaccines, released its second quarter results on August 14, 2025. The most ...
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results